The bacterium amplifies its own receptor, creating a feedback loop that makes infection worse.
In the quiet architecture of the human body, a bacterium that dwells in the mouth has long been suspected of traveling deeper, worsening the slow suffocation of chronic obstructive pulmonary disease in millions worldwide. Researchers have now traced the precise molecular handshake — a protein called FadA reaching for a receptor called cadherin-11 on lung cells — that allows Fusobacterium nucleatum to invade, inflame, and accelerate destruction. Published in PLOS Pathogens, the work transforms a clinical suspicion about oral and respiratory health into a mapped mechanism, and in doing so, points toward a therapeutic interruption that could slow one of humanity's most lethal chronic diseases.
- COPD already claims roughly three million lives each year, and evidence now shows that a common gum-disease bacterium is actively worsening that toll by exploiting a specific molecular doorway into lung tissue.
- Fusobacterium nucleatum does not merely drift into the lungs passively — it uses its FadA surface protein to bind cadherin-11 receptors, and then induces lung cells to produce more of that very receptor, engineering its own escalating invasion.
- Once inside, the bacterium ignites a MAPK13/JUN inflammatory cascade that floods tissue with cytokines including TNF-α and TGF-β, recruiting immune cells and accelerating the lung function decline already measured in COPD patients with higher cadherin-11 levels.
- Laboratory experiments confirmed the mechanism's centrality: blocking or silencing cadherin-11 sharply reduced bacterial adhesion and invasion, while neutralizing FadA with antibodies suppressed the inflammatory surge entirely.
- The findings reframe dental health as a direct variable in respiratory disease progression, and position the FadA-cadherin-11 binding interface as a concrete, targetable point for future therapeutics aimed at slowing COPD in patients with concurrent oral infection.
A bacterium responsible for gum disease has a hidden route into the lungs, and a research team in China has now charted it in molecular detail. Their study, published in PLOS Pathogens, centers on Fusobacterium nucleatum — a common resident of dental plaque in people with periodontitis — and its long-suspected role in worsening COPD, the fourth leading cause of death globally.
Clinicians had noticed for years that patients with gum disease tended to fare worse with COPD, but the biological mechanism connecting the two remained unclear. The researchers focused on FadA, a surface protein on F. nucleatum that functions like a grappling hook, latching onto receptors on host cells. In the gut and blood vessels, FadA had been shown to target different cadherin proteins. The question was what it binds in the lungs.
Analyzing lung tissue from COPD patients, the team found that a receptor called cadherin-11 (CDH11) was significantly elevated in severe emphysema. When lung cells were exposed to F. nucleatum or to FadA protein alone, CDH11 expression rose sharply — the bacterium was actively inducing its own receptor. Molecular docking simulations confirmed that FadA and CDH11 bind with high affinity, forming a stable complex.
The functional consequences were striking. When CDH11 was blocked with antibodies or genetically silenced, bacterial adhesion and invasion dropped dramatically. When it was overexpressed, bacterial uptake increased. The receptor was not a passive surface but the critical gateway to infection. Once inside, F. nucleatum activated the MAPK13/JUN signaling pathway, releasing pro-inflammatory cytokines — TNF-α, TGF-β, CCL20, and CSF3 — that damage lung tissue and hasten functional decline. Blocking FadA or silencing CDH11 both suppressed this cascade.
The clinical picture was troubling in its circularity: infection drives CDH11 upregulation, which enables more infection, which drives more inflammation and destruction. In COPD patients, higher CDH11 levels correlated directly with worse lung function scores. The researchers propose that disrupting the FadA-CDH11 handshake — through antibodies, receptor antagonists, or binding-interface inhibitors — could break this cycle, offering a novel therapeutic strategy for COPD patients whose disease is compounded by oral bacterial infection.
A bacterium that lives in the mouth and causes gum disease has a hidden pathway into the lungs, and researchers have now mapped exactly how it gets there and what damage it does once it arrives. The work, published in PLOS Pathogens, identifies a molecular handshake between an oral pathogen called Fusobacterium nucleatum and a receptor protein on lung cells that opens the door to infection and inflammation.
Fusobacterium nucleatum is a common inhabitant of dental plaque in people with periodontitis. For years, clinicians have noticed that patients with gum disease tend to have worse outcomes from chronic obstructive pulmonary disease—COPD, the fourth leading cause of death worldwide, killing roughly three million people annually. The connection seemed plausible: bacteria from the mouth could be aspirated into the lungs during sleep or breathing, seeding infection and worsening an already compromised respiratory system. But the molecular mechanism remained a mystery.
A team led by researchers in China set out to solve it. They focused on a protein called FadA, which sits on the surface of F. nucleatum and acts as a grappling hook, allowing the bacterium to latch onto host cells. Previous work had shown that FadA binds to different cadherin receptors depending on the tissue—one type in the gut, another in blood vessels. The question was: what does it bind to in the lungs?
Using lung tissue samples from COPD patients, the researchers discovered that a cadherin called CDH11 was significantly elevated in severe emphysema compared to mild disease. When they exposed lung cells in culture to F. nucleatum or to purified FadA protein alone, CDH11 expression shot up. The bacteria seemed to be actively inducing their own receptor. Co-immunoprecipitation experiments confirmed that FadA and CDH11 physically interact. Computational modeling—molecular docking and dynamics simulations—showed that the two proteins bind with high affinity and stability, forming a thermodynamically favorable complex.
But binding alone does not explain pathology. The researchers then blocked CDH11 with antibodies or genetically knocked it down in lung cells, and watched what happened when F. nucleatum tried to infect them. Without CDH11, bacterial adhesion and invasion plummeted. Conversely, when they overexpressed CDH11, bacterial uptake increased. The receptor was not just a passive landing pad; it was the critical determinant of whether the bacterium could establish infection.
Once inside, the bacteria triggered a cascade of inflammation. F. nucleatum infection activated a signaling pathway called MAPK13/JUN, which phosphorylates transcription factors and drives the release of pro-inflammatory cytokines: TNF-α, TGF-β, CCL20, and CSF3. These molecules recruit immune cells, damage lung tissue, and accelerate the decline in lung function. Blocking FadA with antibodies prevented this inflammatory surge. Knocking down CDH11 also abolished the MAPK13/JUN activation and cytokine release—but interestingly, it did not prevent FadA from suppressing p53, a tumor suppressor. This suggested that FadA has at least two separate pathways: one that requires CDH11 for inflammation, and another that does not.
The clinical relevance was clear. In COPD patients, higher CDH11 expression correlated with worse lung function, measured by the forced expiratory volume in one second (FEV1). The bacteria were not just infecting passive tissue; they were remodeling it, upregulating the very receptor that allowed them to invade more efficiently. This creates a vicious cycle: infection induces CDH11, which facilitates more infection, which drives more inflammation and tissue destruction.
The researchers propose that blocking the FadA-CDH11 interaction could interrupt this cycle. If the handshake between bacterium and receptor could be prevented—either by neutralizing FadA with antibodies, blocking CDH11 with antagonists, or disrupting the binding interface—then F. nucleatum could not establish infection in the lungs, and the downstream inflammatory cascade would not ignite. For COPD patients with concurrent oral infection, this could mean slowing disease progression and preserving lung function. The work highlights an unexpected connection between dental health and respiratory disease, and offers a concrete molecular target for future therapeutics.
Notable Quotes
Blocking the interaction between FadA and CDH11 can reduce inflammation, suggesting a promising new therapeutic strategy for slowing down COPD in patients infected with F. nucleatum.— Study authors
CDH11 is essential for this inflammatory signaling but dispensable for FadA-mediated p53 suppression, indicating a separate pathway for this oncogenic event.— Study authors
The Hearth Conversation Another angle on the story
So you've identified that this oral bacterium uses a protein called FadA to bind to a lung receptor called cadherin-11. But why does that matter clinically? People have bacteria in their mouths all the time.
The difference is that this particular bacterium, F. nucleatum, doesn't just sit there. When it reaches the lungs—through aspiration or translocation—it actively triggers inflammation. And the inflammation is severe enough to accelerate COPD, a disease that already kills three million people a year. We're not talking about colonization; we're talking about exacerbation.
You mentioned that CDH11 is upregulated in COPD lungs. Does the bacterium cause that upregulation, or does COPD itself cause it, and the bacterium just takes advantage?
That's the elegant part. Both happen. COPD lungs already have elevated CDH11. But when F. nucleatum or its FadA protein is present, CDH11 goes up even further. The bacterium is essentially amplifying its own receptor. It's a feedback loop that makes infection worse.
You blocked CDH11 and the inflammatory response disappeared. But FadA still suppressed p53. That's strange—why would the same protein have two different mechanisms?
It suggests that FadA has multiple functional domains or that it engages different pathways depending on context. The CDH11-mediated pathway drives inflammation through MAPK13/JUN. But p53 suppression might happen through a separate interaction, maybe with a different receptor or through a direct intracellular mechanism. We don't fully understand that pathway yet.
If you block this interaction therapeutically, what happens to the patient? Does the infection clear, or does it just become less inflammatory?
That's the critical question we haven't answered. Blocking FadA-CDH11 would prevent bacterial invasion and reduce inflammation. But whether the immune system can then clear the bacteria, or whether they persist in a dormant state, we don't know. You'd need animal models or clinical trials to find out.
What about patients who don't have periodontitis? Would this therapy help them?
Probably not directly. This mechanism is specific to F. nucleatum infection. If a COPD patient doesn't have this bacterium in their lungs, blocking FadA-CDH11 wouldn't change anything. But screening for F. nucleatum in COPD patients could identify a subset who might benefit from this targeted approach.